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Autoantibodies (AAbs) to tumor-associated antigens (TAAs) have been identiﬁed in the sera of cancer patients. In a previous
review published in this journal, we have focused on recent knowledge related to circulating AAbs to individual TAAs in breast
carcinoma. This review will focus on recent knowledge related to AAb assays to tailor-made panels of TAAs in breast carcinoma.
So far, AAb assaysto the followingtailor-made panels of TAAs have been assessedin breast carcinoma:(1) p53, c-myc, HER2, NY-
ESO-1, BRCA2, and MUC1, (2) IMP1, p62, Koc, p53, c-MYC, cyclin B1, and survivin, (3) PPIA, PRDX2, FKBP52, HSP-60, and
MUC1, (4) MUC1, HER2, p53, and IGFBP2, (5) p53, HER2, IGFBP-2, and TOPO2α, (6) survivin and livin, (7) ASB-9, SERAC1,
and RELT, and (8) p16, p53, and c-myc. Assessment of serum AAbs to a tailor-made panel of TAAs provides better sensitivity
to diagnosis of breast carcinoma than measuring serum AAbs to a single TAA. Nevertheless, measurement of serum AAbs to a
panel of TAAs for screening and early diagnosis of breast carcinoma is still investigational and should be carried out along with
traditional diagnostic studies.
1.Introduction
The development of circulating autoantibodies (AAbs) to
tumor-associated antigens (TAAs) has been observed to be
associated withcancer[1,2].Unliketraditional tumormark-
ers (e.g., CA-15-3, CA-19-9, CA-125, and CEA), which are
soluble proteins shed by bulky tumors, serum AAbs to TAAs
are detectable even before the tumor is overt clinically [2].
Indeed,Chapmanetal.[3]reported andpresented datafrom
breast carcinoma patients that conﬁrmed that AAbs to TAAs
can be measured up to four years before mammography
imaged the tumor. These striking data imply that the human
immune system detects the TAAs as “nonself” and makes a
humoral immune response very early in the disease process.
The number of women newly diagnosed with breast
carcinoma in the USA during 2010 has been estimated to be
207,090 with an age-adjusted incidence of 121.8 per 100,000
women [4].The number ofwomen deadofbreast carcinoma
in the USAduring 2010has beenestimated to be 39,840with
a death rate of 13.1 per 100,000 women [4]. In the USA,
breast carcinoma is the ﬁrst most common cancer among
women (28% of all cancers in women) and the second most
common cause of death from cancer, after lung carcinoma,
in women (15% of all cancer deaths in women) [4]. The
National Cancer Institute (NCI) has estimated that 12.2%
(1/8)ofwomenborntodayintheUSAwillbediagnosedwith
breastcarcinomaatsometimeintheirlives[5].Nevertheless,
the ﬁve-year survival rate overall of women with breast
carcinoma in the USA is about 90% [6].
Worldwide, breast carcinoma is by far the most frequent
cancer among women with an estimated 1.38 million new
cases diagnosed in 2008 (23% of all malignancies in women)2 Journal of Oncology
andrankssecondoverall(10.9%),afterlungcarcinoma,ofall
malignancies in both sexes [7]. The estimated incidence of
breast carcinoma in 2008 worldwide has been 39 new cases
per 100,000 women. The incidence has been estimated to
vary from 19.3 in Eastern Africa to 89.9 in Western Europe,
and is high (>80) in developed countries (except Japan)
and low (<40) in most of the developing countries [7].
Breast carcinoma has been estimated to cause 458,000deaths
in 2008 worldwide (13.7% of all cancer deaths in women
and 6% of all cancer deaths in both sexes). The estimated
mortality frombreast carcinoma in 2008worldwide hasbeen
12.5deathsper100,000women.Breastcarcinomaisthemost
frequent cause of death from cancer in women worldwide
and the ﬁfth cause of death from cancer, after lung, stomach,
liver, and colorectal carcinoma, in both sexes [7].
Current screening modalities for breast carcinoma diag-
nosis include mammography, ultrasound (US), and mag-
netic resonance imaging (MRI); however, there is still an
urgent need to develop an alternative modality of screening
for earlier diagnosis [8]. The use of serum-soluble tumor
antigens, such as CA-15-3 glycoprotein, as biomarkers for
detection of breast carcinoma has been limited by their
insuﬃcient speciﬁcity and sensitivity, particularly for organ
conﬁned early-stage disease. Consequently, CA-15-3 is not
recommended for use in the screening or detection of breast
carcinoma [9–12]. This is in part due to the elevation of
CA-15-3 in benign conditions including breast, liver, and
kidneydisordersandothercancers[13].Thus,thereisaneed
to discover novel biomarkers, such as serum AAbs to spe-
ciﬁc breast carcinoma TAAs, for screening, early diagnosis,
prediction of prognosis, and monitoring of treatment. Thus
far, only few circulating AAbs to speciﬁc breast carcinoma
TAAs have been identiﬁed and investigated [14]. In breast
carcinoma, like in other malignancies, the use of tailor-made
panel of TAAs, rather than individual TAAs, enhances the
likelihoodofdetectingcancer-associatedAAbswithpotential
diagnostic value.
In apreviousreview publishedintheJournalof Oncology,
we have focused on recent knowledge related to circulating
AAbs to individual TAAs in breast carcinoma [14]. This
review will focus on recent knowledge related to AAb assays
to tailor-made panels of TAAs in breast carcinoma. Table 1
summarizes the results of AAb assays to tailor-made panels
of TAAs in breast carcinoma.
2.AutoantibodyAssayto aPanel of Tumor-
AssociatedAntigensComprisedofp53,c-myc,
HER2,NY-ESO-1,BRCA2,and MUC1
Chapmanetal. [3] examined by enzyme-linked immunosor-
bent assay (ELISA) the presence of AAbs to each of the fol-
lowing seven TAAs: p53, c-myc, HER2, NY-ESO-1, BRCA1,
BRCA2, and MUC1 in the sera of 97 breast carcinoma
patients, 40 ductal carcinoma in situ patients, and 94 normal
controls. Positive seroreactivity was deﬁned as an absorbance
value greater than the mean plus 2 standard deviations of the
normal cohort.The frequencyofAAbstoindividual antigens
ranged from 8% to 34% in breast carcinoma and 3% to 23%
in ductal carcinoma in situ. This corresponded to a signiﬁ-
cantly higher frequency of AAbs to each of the following six
TAAs: p53, c-myc, HER2,NY-ESO-1,BRCA2,and MUC1,in
breastcarcinomapatientscomparedtocontrolsandinductal
carcinoma in situ patients compared to controls. There was
no signiﬁcant diﬀerence, however, in the presence of AAbs
to BRCA1 between breast carcinoma patients and controls,
and between ductal carcinoma in situ patients and controls.
UsinganAAbassaytoapanelcomprisedofthesixTAAs,that
each of them had elicited a signiﬁcant higher rate of positive
seroreactivity compared to controls (p53, c-myc, HER2, NY-
ESO-1, BRCA2, and MUC1), revealed that AAbs to at least
one of the six antigens were detected in the sera of 62/97
breast carcinoma patients and 18/40 ductal carcinoma in
situ patients [3]. This corresponded to a sensitivity of 64%
for breast carcinoma and a sensitivity of 45% for ductal
carcinoma in situ. The speciﬁcity of AAb assay to individual
antigens ranged from 91% to 98% for both breast carcinoma
and ductal carcinoma in situ.T h es p e c i ﬁ c i t yo ft h eA A b
assay to the panel comprised of the above six TAAs was
85% for both breast carcinoma and ductal carcinoma in situ
patients [3]. It has, thus, been shown that measuring AAbs
to a tailor-made panel of TAAs provides better sensitivity
than measuring AAbs to a single TAA. It has been suggested
that AAb assay to a tailor-made panel of TAAs could be used
as an aid to mammography in the detection of early breast
carcinoma, especially in younger women at increased risk
of breast carcinoma where mammography is known to have
reduced sensitivity and speciﬁcity [3]. Moreover, with use of
prototype assays for three TAAs, p53, c-myc, and MUC1, 6/9
(67%) women were reported to show AAbs between 7 and
27 months before the cancer was diagnosed on the screening
mammograms. Further followup has conﬁrmed that 9/15
(60%) patients in a larger cohort showed AAbsdetectable up
to 4 years before mammographic detection [3].
3.AutoantibodyAssayto a Panel ofTumor-
AssociatedAntigensComprisedofIMP1,p62,
Koc, p53,c-MYC,CyclinB1, and Survivin
Zhang et al. [15] examined by ELISA multiplex system the
presence of AAbs to seven TAAs, IMP1, p62, Koc, p53, c-
MYC, cyclin B1, and survivin, in the sera of 527 cancer
patients (64, breast carcinoma; 45, colorectal carcinoma;
91, gastric carcinoma; 65, hepatocellular carcinoma; 56,
lung carcinoma; and 206, prostate carcinoma) and 346
normal subjects. Positive seroreactivity was deﬁned as an
absorbance value above the mean plus 3 standard deviations
of the normal cohort. In all types of cancer tested, although
antibody frequencies to any individual TAA were variable
and rarely exceeded 15%–20%, the successive addition of
TAAs to the array to a total of seven antigens was associated
w i t has t e p w i s ei n c r e a s eo fp o s i t i v eA A br e a c t i o n su pt oa
range of44%–68%[15].In thesera of64patients with breast
carcinoma, the successive addition of TAAs to the array to a
totalofsevenantigenswasassociatedwithastepwise increase
of positive AAb reactions up to 43.8% [15]. It has been
concluded that detection of AAbs in cancer can be enhancedJournal of Oncology 3
Table 1: AAb assays to tailor-made panels of TAAs in breast carcinoma.
Panel of TAAs Serum samples Results of AAb assay Comment Reference
p53, c-myc, HER2,
NY-ESO-1,
BRCA2, and
MUC1
97 IBC patients (mean age,
59 ±12), 40 DCIS patients
(meanage, 59±11), and 94
controls (50 healthy blood
donors and 44 women
(mean age, 54 ± 11) with
normalmammogram).
64% (62/97) of IBC patients and 45%
(18/40) of DCIS patients were seropositive
for at least one of the six TAAs.
This corresponded to a sensitivity of 64%
and 45% for IBC and DCIS, respectively,
and speciﬁcity of 85% for both IBC and
DCIS.
Positive seroreactivity was
deﬁned as an ELISA
absorbance value greater
than the mean + 2 SDs of
the normalcohort. No
correlation was found with
age, tumor size, histologic
grade, lymph node status,
or detection method.
[3]
IMP1, p62, Koc,
p53, c-MYC, cyclin
B1, and survivin
64 IBC Chinese patients, 82
healthy Chinese subjects,
264 healthy USA subjects,
62 SLE USA patients, and
41 SS USA patients.
43.8% (28/64) of IBC Chinese patients were
seropositive for at least one of the seven
TAAs. This was signiﬁcantly higher
(P<. 001) than 11% (9/82) of healthy
Chinese subjects and 9.9% (26/264) of
healthy USA subjects. Using classiﬁcation
trees based on recursive partitioning yielded
as e n s i t i v i t yo f>70%.
Positive seroreactivity was
deﬁned as an ELISA
absorbance value above the
mean + 3 SDs of the
healthy Chinese subjects.
Only 3% (3/62) and 0%
(0/41) of SLE and SS
patients, respectively, were
seropositive.
[15, 16]
Discrimination between IBC patients and
healthy controls gave a ROC AUC of 0.73
(95% CI, 0.60–0.79) with a sensitivity of
55.2%, a speciﬁcity of 87.9%, and a
diagnostic accuracy of 75.1%.
Deﬁnition of positive
seroreactivity was not
reported. Except for age of
DCIS patients, no
correlation was found with
histologic type and grade,
tumor size, lymph node
status, and absence or
presence of ER, PR and
HER-2.
PPIA, PRDX2,
FKBP52, HSP-60,
and MUC1
60 early-stage IBC patients,
82 DCIS patients, and 93
matched healthy controls
(mean age, 55).
Discrimination between DCIS patients of all
ages and healthy controls gave a ROC AUC
of 0.80 (95% CI, 0.71–0.85) with a
sensitivity of 72.2%, a speciﬁcity of 72.6%,
and a diagnostic accuracy of 72.4%.
[17]
Discrimination DCIS patients under 50
years of age and healthy controls gave a ROC
AUC of 0.85 (95% CI, 0.61–0.92) with a
sensitivity of 73.6%, a speciﬁcity of 81.6%, a
diagnostic accuracy of 73.4%, a predictive
positive value of 67.3%, and a negative
predictive value of 85.7%.
MUC1, HER2,
p53, and IGFBP2
Number of patients and
controls was not reported.
18% of patients had
early-stage IBC and 82%
had late-stage IBC. Age
range, 18–75 years.
Controls were age- and
gender-matched.
31% of IBC patients were seropositive for at
least one of the four TAAs. Seropositive rate
for healthy controls was not reported.
Positive seroreactivity was
deﬁned as an ELISA
absorbance value greater
than the mean + 3 SDs of
the normalcohort.
[1]
p53, HER2,
IGFBP-2, and
TOPO2α
184 late-stage IBC patients
(most of them received
prior treatment) and 134
healthy controls.
Discrimination between IBC patients and
healthy controls gave a ROC AUC of 0.63
(P<. 001). Using an algorithm weighted on
logistic regression coeﬃcients resulted in an
AUC of 0.7 (P<. 001).
Positive seroreactivity was
deﬁned as an ELISA
absorbance value greater
than the mean + 3 SDs of
the normalcohort.
[1]
Survivin and livin
46 IBC patients and 10
healthy controls (blood
donors).
52.2% (24/46) of IBC patients were
seropositive for at least one of the two TAAs.
Seropositive rate for healthy controls was
not reported; however, the diﬀerence
between IBC patients and healthy controls
was reported to be statistically signiﬁcant
(P<. 05).
Positive seroreactivity was
deﬁned as an ELISA
absorbance value greater
than the mean + 2 SDs of
the normalcohort. No
correlation was found with
tumor size, lymph node
status or distant metastasis.
[18]4 Journal of Oncology
Table 1: Continued.
Panel of TAAs Serum samples Results of AAb assay Comment Reference
ASB-9, SERAC1,
and RELT
87 IBC patients and 87
normalcontrols.
80.4% (70/87) of IBC patients were
seropositive for at least one of the three
TAAs. Discrimination between IBC patients
and healthy controls gave a ROC AUC of
0.861 with a sensitivity of 80% and a
speciﬁcity of 100% (P = .0001).
Deﬁnition of positive
seroreactivity was not
reported. AAbs were
measured by phage protein
ELISAs. A logistic
regression model and
leave-one-out validation
was used to evaluate
predictive accuracies.
[19]
p16, p53, and
c-myc
41 IBC patients and 82
normalcontrols.
43.9% (18/41) of IBC patients and 2.4%
(2/82) of normal controls were seropositive
for at least one of the three TAAs (P<. 01).
This corresponded to a sensitivity of 43.9%,
speciﬁcity of 97.6%, false negative rate of
56.1%, false positive rate of 2.4%, positive
predictive value of 90%, and negative
predictive value of 77.7%.
Positive seroreactivity was
deﬁned as an ELISA
absorbance value greater
than the mean + 3 SDs of
the normalcohort.
[20]
AAb: autoantibody; TAA: tumor-associated antigen; IBC: invasive breast carcinoma; DCIS: ductal carcinoma in situ; SD: standard deviation; SLE: systemic
lupus erythmatosus; SS: Sjogren’s syndrome; ROC: receiver operating characteristic curve; AUC: area under curve; CI: conﬁdence interval; ER: estrogen
receptor; PR: progesterone receptor.
by using a miniarray of several TAAs as target antigens
[15, 21].
Koziol et al. [16] have analyzed the data of Zhang et al.
[15] by classiﬁcation trees based on the statistical method
of recursive partitioning [22, 23]. By this method, Koziol
et al. [16] have demonstrated that AAb assay to the tailor-
made panel of the seven TAAs used by Zhang et al. [15]c a n
discriminate between cancer patients and normal controls
withreasonablyhighsensitivityandspeciﬁcity,bothtypically
exceeding 0.80. In breast carcinoma, using normal mean +
3SDs as cutoﬀ for positivity yielded a sensitivity of 70%
and speciﬁcity of 95%, whereas using normal mean + 2SDs
as cutoﬀ for positivity yielded a sensitivity of 92% and
speciﬁcity of 85% [16]. The authors [16] concluded that
classiﬁcation trees based on a panel of seven TAAs can
discriminate between breast carcinoma patients and normal
subjects with reasonably high sensitivity and speciﬁcity. The
multivariate approach of recursive partitioning using AAb
assay to a tailor-made panel of TAAs yielded far higher
values of sensitivity and speciﬁcity than an AAb assay to
individual TAAs [16]. It has been concluded that multiple
antigen miniarrays can provide accurate and valuable tools
for cancer detection and diagnosis. Performance of the
miniarrays might be enhanced by other combinations of
TAAs appropriately selected for diﬀerent cancer cohorts [16,
21].
4.AutoantibodyAssayto aPanel of
Tumor-AssociatedAntigensComprisedof
PPIA,PRDX2, FKBP52,HSP-60,andMUC1
Desmetz et al. [17] examined the feasibility of using an AAb
assay to a panel of TAAs as a method for early detection
of breast carcinoma and, more particularly, carcinoma in
situ. The authors examined by ELISA the presence of AAbs
to ﬁve individual TAAs, PPIA, PRDX2, FKBP52, HSP-60,
and MUC1, in sera from 60 breast carcinoma patients, 82
breast carcinoma in situ patients, and 93 healthy controls.
Three of the ﬁve individual TAAs, FKBP52, PPIA, and
PRDX2, showed signiﬁcantly increased reactivity in breast
carcinoma patients and breast carcinoma in situ patients
compared to healthy controls. When combined into a panel,
the ﬁve TAAs signiﬁcantly discriminated breast carcinoma
(receiver operating characteristic (ROC) area under the
curve (AUC), 0.73; 95% conﬁdence interval (CI), 0.60–
0.79) and breast carcinoma in situ (ROC AUC, 0.80; 95%
CI, 0.71–0.85) from healthy individuals. Importantly, the
ROC AUC value of the panel was able to distinguish breast
carcinoma in situ, including high grades, from healthy
controls in women under the age of 50 years (ROC AUC,
0.85; 95% CI, 0.61–0.92). The authors [17] conclude that
their AAb assay to a panel comprised of ﬁve TAAs allows
for an accurate discrimination between early-stage breast
carcinoma, especially breast carcinoma in situ,a n dh e a l t h y
individuals. These results could be of interest in detecting
early breast carcinoma as an aid tomammography, especially
in women younger than 50 years.
5.AutoantibodyAssayto a Panel of
Tumor-AssociatedAntigensComprisedof
MUC1, HER2,p53 and IGFBP2
Lu et al. [1] haveassessed thevalueofan AAbassay toa panel
of TAAs comprised of MUC1, HER2, p53 and IGFBP2 as
a diagnostic tool for breast carcinoma. Although the serum
AAb response rate to the best performing single antigen,Journal of Oncology 5
MUC1, was no more than 20%, addition of HER2 to the
panel increased the percent of positive samples to 25%, and
addition of p53, and IGFBP2 increased the rate of positivity
to 31% [1]. Thus, 31% of the breast carcinoma patients
analyzed with an AAb assay to a panel of TAAs comprised
of MUC1, HER2, p53, and IGFBP2 had serum AAbs to at
least one of the four TAAs tested, suggesting that diagnostic
sensitivity may be improved by using AAb assay to a panel of
TAAs for detection of breast carcinoma.
6.AutoantibodyAssayto aPanel of
Tumor-AssociatedAntigensComprisedof
p53,HER2,IGFBP-2, andTOPO2α
Lu et al. [1]testedtheseraof184advanced-stage breastcarci-
noma patients and 134 healthy controls for AAb response to
p53, HER2, IGFBP-2, and TOPO2α, and the responses were
used to construct receiver operating characteristic (ROC)
curves. They have found that response to p53 alone was not
a signiﬁcant predictor of breast carcinoma (area under the
curve (AUC) = 0.48, P = .538), but combining responses to
twoantigens(p53andHER2)resultedinanAUC=0.61(P =
.006), and combining responses to all of the four antigens
increased the AUC to 0.63 (P = .001). Using an algorithm
weighted on logistic regression coeﬃcients of AAb response
to individual TAAs resulted in an AUC of 0.7 (P<. 001) [1].
The authors[1]concludedthat using an AAbassay toa panel
of TAAs is more eﬃcient at discriminating breast carcinoma
patients from healthy controls than the use of an AAb assay
toasingle TAA.Nevertheless,theserum samples testedbyLu
et al. [1] were obtained from patients with advanced-stage
disease; whether the ﬁndings apply to patients with early-
stage breast carcinoma remains to be investigated.
7.AutoantibodyAssayto aCoupletof
Tumor-AssociatedAntigensComprised
of Survivin and Livin
Survivin and livin are inhibitors of apoptosis protein (IAP).
Yagihashi et al. [18]examinedbyspeciﬁcELISAusingrecom-
binantproteintheprevalenceofAAbstosurvivin andlivin in
the sera of 46 breast carcinoma patients. With use of a cutoﬀ
value for positivity determined as the mean absorbance +
2SDs for healthy controls, 11/46 (23.9%) and 15/46 (32.6%)
breast carcinoma patients were seropositive for survivin
and livin, respectively. The intensity of anti-survivin AAb
responses did not correlate with intensity of antilivin AAb
responses (r = 0.1628). In addition, the intensities of AAb
responses to survivin or livin did not correlate with tumor
size,lymphnodestatus,ordistantmetastasis.However,when
the AAb assay was activated to survivin and livin combined
into a panel, 24/46 (52.2%) patients were seropositive for
at least one of the two TAAs [18]. It has, thus, been shown
thatthediagnostic sensitivitymaybeimprovedbyusingAAb
assaytoacoupletofTAAsrathertoasingleTAAfordetection
of breast carcinoma.
8.AutoantibodyAssayto a Panel of
Tumor-AssociatedAntigensComprisedof
ASB-9,SERAC1,and RELT
Zhong et al. [19] investigated by ELISA the presence of AAbs
to six tumor-associated phage-expressed proteins, KLF17,
C O L 6 A 1 ,G R W D 1 ,A S B - 9 ,S E R A C 1 ,a n dR E L Ti nt h es e r a
from 87 breast carcinoma patients and 87 normal controls.
Each of the three TAAs, ASB-9 (36/87 (41.3%), P = .0112),
SERAC1 (41/87 (47.1%), P = .0009), and RELT (46/87
(52.9%), P = .0001) elicited signiﬁcantly higher frequency
of AAbs in breast carcinoma patients compared to healthy
controls.WhenthesethreeTAAswerecombinedintoapanel,
it was found that 70/87 (80%) breast carcinoma patients had
serum AAbs to at least one of these TAAs. Measurements of
AAbresponsetothesethreeTAAswerecombinedinalogistic
regression model that produced an area under the curve
(AUC) equal to 0.861 in the receiver operating characteristic
(ROC)curveandachievedasensitivity of80%andspeciﬁcity
of 100% in prediction of breast carcinoma (P = .0001). The
authors [19] conclude that the use of AAb assay to a panel of
TAAs, rather than to a single TAA, is a promising approach
for early detection and diagnosis of breast carcinoma.
9.AutoantibodyAssayto a Panel of
Tumor-AssociatedAntigensComprisedof
p16,p53,and c-myc
Looi et al. [20] investigated the sera from 41 breast carci-
noma patients for the presence of AAbs to p16, p53, and
c-myc. They found AAb to p16 in 7/41 (17.1%), AAb to
p53 in 5/41 (12.2%), and AAb to c-myc in 9/41 (22%)
breast carcinoma patients. This corresponded to signiﬁcant
increased frequency for AAbs to each of these three TAAs
in breast carcinoma patients compared to healthy controls
(P<. 01). When these three TAAs were combined into a
panel, it was found that 18/41 (43.9%) breast carcinoma
patients had serum AAbs to at least one of these TAAs. It
has, thus, been shown that with the successive addition of
TAAs to the panel, there is a stepwise increase of positive
AAb reaction with increased sensitivity for diagnosis of
carcinoma. The authors [20] concluded that it is conceivable
that AAbproﬁles involving diﬀerentpanelsor arraysofTAAs
m i g h tb ed e v e l o p e di nt h ef u t u r ea n dt h er e s u l t sc o u l db e
useful for cancer diagnosis.
10.Conclusion
Breast carcinoma is the most common malignancy and
the most frequent cause of death from cancer in women.
Traditionaldiagnostictoolsforearlydetection,namely,man-
ual breast examination, imaging studies (mammography,
ultrasound and MRI), and measurement of serum CA-15-
3, are crippled with insuﬃcient sensitivity and speciﬁcity.
Themeansensitivityofmammography hasbeenestimatedto
be 77% (range: 29–97%) [24–26]. The rate of false-negative
mammography has been reported to be 4–34% [27, 28].
SerumAAbstospeciﬁcTAAsaredetectableincancerpatients6 Journal of Oncology
even when the tumor is obscured clinically. Evidently, the
human immune system recognizes the autologous TAAs as
“nonself” and makes a humoral immune response very early
in the disease process. Thus, the identiﬁcation of serum
AAbs to TAAs could potentially be used as a novel tool
for screening and early diagnosis of breast carcinoma. In a
previousreviewpublishedintheJournalofOncology,w eha v e
focused on recent knowledge related to circulating AAbs to
individual TAAs in breast carcinoma [14]. In this review, we
have focused on recent knowledge related to AAb assays to
tailor-made panels of TAAs in breast carcinoma. We have
highlighted that measurement of AAbsto tailor-made panels
of TAAs may have better promising diagnostic potential
with greater sensitivity and speciﬁcity than assessment of
AAbs against a single TAA. The implications of this would
be that AAbs to tailor-made panels of breast carcinoma
TAAs would provide a simple blood test for screening and
early diagnosis of breast carcinoma. Nevertheless, it must be
remembered that measurement of serum AAbs either to a
single TAA or to a tailor-made panel of TAAs for screening
and early diagnosis of breast carcinoma is still investigational
and should be carried out along with traditional screening
and diagnostic studies. Our personal viewpoints regarding
the management of women having a blood test for serum
AAbs to tailor-made panels of breast carcinoma TAAs are
the same as for women having a blood test for serum AAbs
to a single breast carcinoma TAA [14]. Presence of serum
AAbstoatailor-made panel ofbreast carcinoma TAAswould
inﬂuencemanagementasfollows:(1)strengthenthedecision
to perform an immediate breast biopsy to obtain tissue for
histological diagnosis rather than to wait six months for
the next mammography in women with probably benign
ﬁndings on current mammography (BI-RADS category 3)
[29], (2) strengthen the decision to perform an immediate
breast biopsy to obtain tissue for histological diagnosis
rather than to wait one year for the next routine annual
screening mammography in women with benign ﬁnding(s)
on current mammography (BI-RADS category 2) [29],
and (3) strengthen the decision to perform immediate
additional imaging studies (ultrasound and/or MRI) rather
than to wait one year for the next routine annual screening
mammography in women with negative ﬁndings on current
mammography (BI-RADS category 1) [29]. It seems that in
this stage of knowledge the immediate preferred population
for assaying serum AAbs to tailor-made panels of breast
carcinoma TAAs would be younger women (age, <50 years)
inwhommammographic screening interpretationisdiﬃcult
because of dense breasts. The presence of serum AAbs to
tailor-made panels of breast carcinoma TAAs in such women
would hasten the assessment by additional imaging studies
(ultrasound and/or MRI) and might even bring to the
performance of an immediate breast biopsy to obtain tissue
for histological diagnosis.
T h e r ei se v i d e n c et h a tA A b st ob r e a s tc a r c i n o m aT A A s
can be used to detect the malignancy months to years before
current methods such as mammography could detect the
tumor. Since AAb assays to tailor-made panels of TAAs
have a better diagnostic potential than assessment of AAbs
against a single TAA, it seems that AAb assays to panels of
breast carcinoma TAAs have a promising future for breast
carcinoma screening and early detection.
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